Merck KGaA (XTER:MRK) Valuation Rank

View and export this data going back to 1995. Start your Free Trial

What is Merck KGaA Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Merck KGaA Valuation Rank Related Terms

Thank you for viewing the detailed overview of Merck KGaA's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Merck KGaA (XTER:MRK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck KGaA (XTER:MRK) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

MKKGY:USA MKGAF:USA MRK:Italy MRKd:UK 0O14:UK MRCK:Austria

Address

Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293

Website

https://www.emdgroup.com

Merck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (47% of 2022 sales) primarily provides laboratory consumables and services to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (35%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (18%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.

Executives

Belén Garijo Lopez	Chair of the Executive Board
Peter Guenter	Member of the Executive Board
Dr. Matthias Heinzel	Member of the Executive Board
Dr. Marcus Kuhnert	Board of Directors